Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: Tom Allinder who wrote (38526)	3/22/2000 9:07:00 AM
From: StocksDATsoar	Read Replies (1) \| Respond to of 150070

Tom, I bought ACLA at $30.00 yesterday...CNBC will feature the company this morning.. January 20, 2000 ACLARA BIOSCIENCES INC (ACLA) S-1 Filing (SEC form S1) We believe that we are the only microfluidics, or lab-on-a-chip, company with access to the wide range of technology and intellectual property required to broadly address the genomics and pharmaceutical drug screening markets. We are developing multiple products based on our proprietary microfluidics technology that allow researchers to rapidly perform large numbers of chemical and biological measurements in a miniaturized, automated format. In collaboration with our strategic partners, we are developing dedicated analytical instruments that will utilize our LabCard chip products. We believe that these LabCard systems will provide order-of-magnitude increases in throughput and enhanced accuracy for a wide range of laboratory analyses, at a lower cost than current analytical systems. We intend to commercially introduce our initial LabCard product, the Oasis microfluidic array chip, in late 2000. We have strategically partnered with PE Biosystems, a leading provider of analytical systems for genomics and pharmaceutical drug screening. We are combining our proprietary microfluidics technology with their broad platform of technologies, including reagent chemistries, assay methods, instrumentation and software. We also plan to use the marketing, sales and distribution strengths of our current and future partners to successfully commercialize our products. OUR TARGET MARKETS Our technologies address several of the fastest-growing markets in the life sciences industry. In combination, these markets currently total several billion dollars, and we expect them to grow substantially as a result of the dramatic advances in genomics and drug discovery. We currently focus on the major segments of the genomics market -- DNA sequencing, genotyping and gene expression analysis -- as well as key applications in pharmaceutical drug screening. We also expect to develop products for industrial process control and sensing systems as well as clinical diagnostics. OUR TECHNOLOGY AND PRODUCTS Our microfluidic chip technology enables us to move various fluids and materials through microchannel networks, using electric fields to direct the flow of these materials. We design these networks in a grid or array format, enabling researchers to perform multiple measurements in parallel on our LabCard chips. Our microfluidic approach enables the rapid and accurate measurement, dispensing and mixing of volumes as small as one-millionth the volume of a well in a standard 96-microwell plate. In this manner, we can precisely manipulate a variety of fluids, including those that contain whole cells, cell fragments or magnetizable particles, using computerized controls with no moving parts or valves. We are currently developing multiple products for the genomics and pharmaceutical drug screening markets. We believe that our products will offer researchers several key benefits: - Greater Flexibility in Chip Design and Use. We produce most of our chips using advanced plastic materials and proprietary process technologies. We believe that our single-use plastic chips offer substantial advantages over glass chips, including the avoidance of sample or reagent carryover from one measurement to the next and lower manufacturing costs. - Higher Throughput and Avoidance of Cross Contamination. We have designed chips that contain arrays of microfluidic networks, where each network enables analysis of a different sample. This approach increases throughput and avoids cross contamination of different reactions on the same chip. - Greater Information Content. Our LabCard chips and proprietary assay chemistries allow researchers to obtain more information from each measurement than is currently possible with standard microwell plates. - Faster Analysis. Our LabCard chips allow researchers to perform most measurements faster than with conventional instrument systems. For example, we can determine the sequence of a DNA strand in less than 20 minutes on our LabCard chips. A similar experiment often requires over two hours on a capillary array DNA sequencer. - Increased Efficiency and Higher Data Quality. Our LabCard chips decrease the number of human intervention points and reduce the potential for variability and error. - Reduced Cost. Several factors combine to reduce the cost of chemical and biological information obtained from our LabCard chips, including lower labor, reagent and sample costs. OUR STRATEGY Our objective is to be the leading provider of microfluidic chips to large, fast-growing segments of the genomics and pharmaceutical drug screening markets where the information sought is of high value to customers. Key elements of our strategy include: - Partnering With Industry Leaders for Instrument Development, Manufacturing and Commercialization. We intend to use the instrumentation, software, chemistry expertise and distribution strengths of our partners, such as PE Biosystems, to accelerate the development of integrated, microfluidics-based systems. - Leveraging Our Intellectual Property With That of Our Partners. Our broad patent portfolio includes 76 patents and patent applications. We also benefit from the intellectual property portfolio of our strategic partners enabling us to broadly address the genomics and pharmaceutical drug screening markets. - Generating Recurring, High Margin Revenue. We expect that most LabCard systems sold will generate recurring revenue from sales of single-use disposable LabCard chips. We are developing proprietary processes for the cost-effective production of these plastic LabCard chips. - Enhancing the Value of LabCard Systems With Proprietary Chemistries. We intend to integrate proprietary chemistries developed by us and our strategic partners to significantly enhance the flexibility and utility of our LabCard systems. OUR HISTORY We were formed by a spin-off transaction from Soane Technologies, Inc., which was incorporated in 1991 and subsequently changed its name to 2C Optics, Inc. We were incorporated in Delaware in 1995 under the name Soane BioSciences, Inc. and changed our name to ACLARA BioSciences, Inc. in 1998.